Zanidatamab zovodotin is under clinical development by Zymeworks and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zanidatamab zovodotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zanidatamab zovodotin overview

Zanidatamab Zovodotin is under development for the treatment of HER-2 positive breast cancer, brain metastases, endometrial cancer, gastroesophageal adenocarcinoma, gynecologic cancers, non-small cell lung cancer, anal cancer, and colorectal cancer. It is being administered through intravenous route. The drug candidate is an bi-specific antibody-drug conjugate (ADC) targeting HER2. It comprises Azymetric biparatopic anti-HER2 antibody conjugated to proprietary cytotoxic payload via a cleavable linker. It is developed based on Azymetric and Zymelink technology platforms. These technologies enables the production of ADCs with target affinity, effector function and increase in circulation half life. ZW49 delivers a novel auristatin (cell-killing compound) to tumor cells by taking advantage of the enhanced antibody-HER2 internalization of zanidatamab.  

Zymeworks overview

Zymeworks is a clinical stage biopharmaceutical company that discovers, develops and commercializes biotherapeutics for the treatment of cancer, autoimmune and inflammatory diseases. The company product pipeline includes the lead candidate Zanidatamab for the treatment of biliary tract cancers, breast cancer, gastroesophageal adenocarcinomas and colorectal cancer, Zanidatamab Zovodotin for HER2-expressing cancers, ZW191 – TOPO1i antibody drug conjugate for ovarian and gynecological cancers and ZW171 – 2+1 T-Cell for solid tumor. Zymeworks technology platform comprises Azymetric, Zymelink, Efect and Protect. It operates in the US and Canada. Zymeworks is headquartered in Vancouver, British Columbia, Canada.

For a complete picture of Zanidatamab zovodotin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.